Loading
Life sciences · Journal article
Communications Biology · October 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Breast cancer endocrine therapy, including tamoxifen, systemically disrupts estrogen receptor signaling and increases type 2 diabetes (T2D) risk in women. Hyperplastic adipose tissue expansion, especially in subcutaneous depots, facilitates nutrient storage and attenuates inflammation during a chronic positive energy balance and is impaired in the absence of estrogen. Adipocyte progenitors are renewed through Wnt signaling pathway activation, however the the mechanisms that explain the depletion of these cells during endocrine therapy are not defined. Here we show the direct impact of tamoxifen on proliferation, renewal, and differentiation in subcutaneous adipose stromal cells from humans and adult mice. In obesity, the Wnt1 inducible signaling pathway protein 2 (Wisp2) was lost in adipocyte progenitors following endocrine therapy. Wisp2 gain and loss of function studies defined the link between estrogen signaling and adipocyte progenitor maintenance. We found that tamoxifen treatment disrupts the protection of adipocyte progenitors by estrogen, mediated through suppression of Wisp2. These studies reveal effects of tamoxifen therapy that precede and could influence T2D development in breast cancer survivors.